REG - AstraZeneca PLC - Result of AGM

AstraZenecaAnnouncement

11/04/2024 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240411:nRSK3420Ka&default-theme=true

RNS Number : 3420K  AstraZeneca PLC  11 April 2024

11 April 2024 1730 BST

 

Results of Annual General Meeting held on 11 April 2024

 AstraZeneca PLC announced the results of the voting at its Annual General
Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were
decided by poll vote. Resolutions 11 - 14 were passed as special resolutions;
all other resolutions were passed as ordinary resolutions.

     Resolution                                                                   Votes for      % of votes cast  Votes against  % of votes cast  Votes cast in total  Total votes cast as a % of issued share capital  Votes withheld
 1   To receive the Company's Accounts, the Reports of the Directors and Auditor  1,205,690,871  99.88            1,470,816      0.12             1,207,161,687        77.87%                                           9,700,968
     and the Strategic Report for the year ended 31 December 2023
 2   To confirm dividends                                                         1,215,177,590  99.94            790,189        0.06             1,215,967,779        78.44%                                           894,978
 3   To reappoint PricewaterhouseCoopers LLP as Auditor                           1,208,377,872  99.36            7,843,545      0.64             1,216,221,417        78.45%                                           642,048
 4   To authorise the Directors to agree the remuneration of the Auditor          1,215,717,786  99.98            279,816        0.02             1,215,997,602        78.44%                                           722,222
 5a  To re-elect Michel Demaré as a Director                                      1,197,325,871  98.49            18,416,788     1.51             1,215,742,659        78.42%                                           1,120,559
 5b  To re-elect Pascal Soriot as a Director                                      1,206,729,787  99.26            9,036,742      0.74             1,215,766,529        78.42%                                           1,098,706
 5c  To re-elect Aradhana Sarin as a Director                                     1,212,225,383  99.71            3,509,122      0.29             1,215,734,505        78.42%                                           1,129,532
 5d  To re-elect Philip Broadley as a Director                                    1,197,937,103  98.54            17,773,671     1.46             1,215,710,774        78.42%                                           1,153,360
 5e  To re-elect Euan Ashley as a Director                                        1,213,332,278  99.80            2,375,199      0.20             1,215,707,477        78.42%                                           1,156,567
 5f  To re-elect Deborah DiSanzo as a Director                                    1,215,396,504  99.97            318,525        0.03             1,215,715,029        78.42%                                           1,149,106
 5g  To re-elect Diana Layfield as a Director                                     1,215,424,019  99.98            292,514        0.02             1,215,716,533        78.42%                                           1,147,602
 5h  To elect Anna Manz as a Director                                             1,215,297,866  99.97            417,067        0.03             1,215,714,933        78.42%                                           1,149,091
 5i  To re-elect Sheri McCoy as a Director                                        1,158,846,767  95.32            56,874,293     4.68             1,215,721,060        78.42%                                           1,142,920
 5j  To re-elect Tony Mok as a Director                                           1,215,346,936  99.97            346,157        0.03             1,215,693,093        78.42%                                           1,170,931
 5k  To re-elect Nazneen Rahman as a Director                                     1,191,449,316  98.59            16,988,178     1.41             1,208,437,494        77.95%                                           8,426,242
 5l  To re-elect Andreas Rummelt as a Director                                    1,215,395,253  99.97            314,359        0.03             1,215,709,612        78.42%                                           1,154,412
 5m  To re-elect Marcus Wallenberg as a Director                                  947,479,100    77.93            268,252,536    22.07            1,215,731,636        78.42%                                           1,132,416
 6   To approve the Annual Report on Remuneration for the year ended 31 December  1,158,470,360  95.32            56,835,406     4.68             1,215,305,766        78.40%                                           1,558,941
     2023
 7   To approve the Directors' Remuneration Policy                                761,702,826    64.43            420,514,520    35.57            1,182,217,346        76.26%                                           34,645,873

 8   To approve amendments to the AstraZeneca Performance Share Plan 2020         769,577,451    65.34            408,204,003    34.66            1,177,781,454        75.97%                                           39,083,170

 9   To authorise limited political donations                                     1,184,223,861  98.00            24,219,787     2.00             1,208,443,648        77.95%                                           8,278,265
 10  To authorise the Directors to allot shares                                   1,129,625,915  92.94            85,836,406     7.06             1,215,462,321        78.41%                                           1,259,562
 11  To authorise the Directors to disapply pre-emption rights                    1,044,559,011  85.95            170,708,848    14.05            1,215,267,859        78.39%                                           1,454,048
 12  To authorise the Directors to further disapply pre-emption rights for        997,629,834    82.33            214,143,713    17.67            1,211,773,547        78.17%                                           4,948,031
     acquisitions and specified capital investments
 13  To authorise the Company to purchase its own shares                          1,205,828,976  99.23            9,306,860      0.77             1,215,135,836        78.38%                                           1,585,923
 14  To reduce the notice period for general meetings                             1,131,157,449  93.07            84,269,754     6.93             1,215,427,203        78.40%                                           1,294,801

 

A copy of the resolutions passed at the AGM (other than resolutions concerning
ordinary business) has been submitted to the National Storage Mechanism for
publication, and will shortly be available for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 Statement in connection with resolutions 5m, 7 and 8

AstraZeneca is pleased that all resolutions were supported at today's Annual
General Meeting. In particular, the Board thanks the majority of our
shareholders who have supported the Remuneration Policy (the Policy) and will
continue to engage with our shareholders and the proxy advisors to explain our
need for global benchmarks and pay for performance, which is driven by the
Policy.

We will publish an update on the engagement with shareholders on resolutions
5m, 7 and 8 and on any action taken as a result within six months of today's
AGM, in accordance with the UK Corporate Governance Code.

Issued capital

As at 9 April 2024, the number of issued shares of the Company was
1,550,231,084 ordinary shares, which was the total number of shares entitling
the holders to attend and vote for or against all of the resolutions at the
AGM. In accordance with the Company's Articles of Association, on a poll every
member present in person or by proxy has one vote for every share held.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on social media @AstraZeneca (http://www.twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGGPUUPCUPCGQG